Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis: Bryan Dechairo, Roald Borré

Biocartis said this week that Roald Borré has resigned as director of the company, and Bryan Dechairo has been appointed as a new independent board member and a member of the company's audit committee. Dechairo is CEO of Sherlock Biosciences and serves on that company's board of directors. Prior to joining Sherlock, Dechairo was executive VP of clinical development at Myriad Genetics. Before that, he was chief medical officer, CSO, and senior VP of R&D at Assurex Health, which Myriad acquired in 2016. Earlier, Dechairo held roles of increasing responsibility at companies including Medco, Pfizer, Oxagen, Sequana and Roche. He holds a PhD in common complex human genetics from the Institute of Child Health at University College London and a BA in integrative biology from the University of California, Berkeley.